Summary
- Closed for EoI
- Profile Type
- Research & Development Request
- POD Reference
- RDRES20230302015
- Term of Validity
- 2 March 2023 - 1 March 2025
- Company's Country
- Spain
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The Spanish innovative SME is working on premium pro and postbiotics and microbiome science to prevent & regulate metabolic glucose metabolism (diabetes). The company is proprietary to a bacteria collection and microbiota and their efforts related on IP actions and science have a strong strategy in place. The company is seeking for partners to jointly apply to Eurostars3.
- Full Description
-
A Spanish biotech SME with deep experience on R&D, industrial development and commercialization on premium probiotics and postbiotic ingredients, set-up of pioneer technology and fast efficacy tests/models for glycemic metabolism regulation. The company studies the central role of pro-/postbiotics as modulators on the gut microbiota and their MoA to improve glucose metabolism (hyperglycemia) towards precision and personalized medicine on diabetes.
They aim to integrate and deep greater knowledge on other strains, strain combination as well as insight at the level of postbiotic fractions of PA1c or metabolites involved in the regulation of glycemia (novel strategy) towards precision medicine. Minor subcontracting is planned to assist technically the SME in cell fractionation. Likewise, of interest for them, collaboration to their developed fast pre-screening C. elegans model for efficacy testing of probiotic strains or metabolites for personalized approach on diabetes.
Further commercial agreements thanks to association for this Eurostars3 are possible by strengthening a potential join venture with defined competencies at marketing level.
Seeking partners and roles: Preferably innovative SME´s with expertise on non-invasive continuous Blood Glucose/HbA1c Monitoring Systems (e.g.:glucometers) to provide key information. Open additionally to research centers, universities, enterprises, large companies and other type of organisation on food and pharma industries, interested in leading. mainly from food/pharma sectors & scientific environment.
Call: EUROSTARS3 (April 2023) & other EU PROJECTS. - Advantages and Innovations
-
• Fast efficacy pre-screening in vivo model with C. elegans: strain selection & other compound combinations.
• MoA study on effectiveness on glycemic metabolism in C.elegans.
• Preclinical analysis of the long-term efficiency (probiotics, postbiotics) in rodents.
• Metagenomic studies on impact on intestinal microbiota in rats.
• Metabolomic studies on the potential activity on glycemic regulation in C.elegans.
• Nutritional intervention trials to assess glycemic control, and microbiota composition in humans.
ADVANTAGES
-Unique: pA1c© single-strain and pA1cHI© postbiotic for long-term and continuous glycemic regulation.
-Expertise on long-term regulating hyperglycemia & gut microbiota.
-Strong IP position. Published International: (WO 2021/123355).
-Safe (QPS, EFSA)
-Profitable industrial processes associated with the type of strain that reduce the cost of production by 75% compared to the only reference on the market (best price).
-Vegetable-based ingredients in a registered food facility (applicable GMP standards)
-Natural, Allergen free, non-GMO, nanocapsule-free probiotics
-Ready for Consumer Health market (affordable) - Technical Specification or Expertise Sought
-
Partner Type and Expertise: Microbiome and Probiotic sector, preferentially innovative SMEs, open additionally to Research Centers, Universities, Enterprises, Large Companies and other type of organisation on Food and Pharma Industries.
Experts on non-invasive continuous Blood Glucose/HbA1c Monitoring Systems for Diabetes.
Other know-how of interest: Bioinformatics methods of “omics” technologies for application on human microbiological systems, compositional microbiota analysis, metagenomics and metatranscriptomics. interventional nutritional and clinical trials related to metabolic diseases, co-development of food supplement and functional foods, medical devices for diabetes, Sequencing Platform. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 12: Responsible Consumption and Production
- Goal 13: Climate Action
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
-
The enterprise is looking for:
Currently: Partners/consortium interested in participating in EUROSTARS3 (April 2023), as current priority, & another EU projects/programmes.
Strategic consortium/partners preferentially SME´s with expertise on non-invasive continuous monitoring devices (glucometers) for Glycemia/HbA1c measurement. Mainly from food and pharma sectors and in the scientific environment, for international market and product development (EU projects) they are looking for long-lasting and successful cooperation and distribution agreements. - Type and Size of Partner
- SME 11-49
- R&D Institution
- University
- SME <=10
- SME 50 - 249
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- International cooperation
- Call title and identifier
-
EUREKA-EUROSTARS 3
- Submission and evaluation scheme
-
April 2023
- Coordinator required
-
Yes
- Deadline for EoI
- Deadline of the call
- Project duration in weeks
-
32
- Web link to the call
- https://www.eurekanetwork.org/blog/eurostars-3-a-key-instrument-for-horizon-eur…
- International cooperation
Dissemination
- Technology keywords
- 08001002 - Food Additives/Ingredients/Functional Food
- 06006003 - Biobased chemical building blocks
- 006001002 - Care and Health Services
- 06006011 - Fermentation
- 06001008 - Environmental Medicine, Social Medicine, Sports Medicine
- Market keywords
- 04010 - Microbiology
- 05007002 - Pharmaceuticals/fine chemicals
- 04007 - Enzymology/Protein Engineering/Fermentation
- 07003002 - Health food
- Sector Groups Involved
- Health
- Agri-Food
- Targeted countries
- All countries